<SEC-DOCUMENT>0001193125-20-161343.txt : 20200605
<SEC-HEADER>0001193125-20-161343.hdr.sgml : 20200605
<ACCEPTANCE-DATETIME>20200605065303
ACCESSION NUMBER:		0001193125-20-161343
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20200605
DATE AS OF CHANGE:		20200605
EFFECTIVENESS DATE:		20200605

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MEDNAX, INC.
		CENTRAL INDEX KEY:			0000893949
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-HOSPITALS [8060]
		IRS NUMBER:				263667538
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12111
		FILM NUMBER:		20944639

	BUSINESS ADDRESS:	
		STREET 1:		1301 CONCORD TERRACE
		CITY:			SUNRISE
		STATE:			FL
		ZIP:			33323
		BUSINESS PHONE:		9543840175

	MAIL ADDRESS:	
		STREET 1:		1301 CONCORD TERRACE
		CITY:			SUNRISE
		STATE:			FL
		ZIP:			33323

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PEDIATRIX MEDICAL GROUP INC
		DATE OF NAME CHANGE:	19950801
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>d921216ddefa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<HTML><HEAD>
<TITLE>DEFA14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section 13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (date of earliest event reported): June 5, 2020 </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>MEDNAX, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
Name of Registrant as Specified in Its Charter) </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Florida</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-12111</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>26-3667538</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>1301 Concord Terrace </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Sunrise, Florida 33323 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) (zip code) </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code (954) 384-0175 </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">N/A </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or former
address, if changed since last report.) </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
</P></TD></TR></TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section 12(b) of the Act: </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of each class</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Trading</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Symbol(s)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of each exchange</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>on which registered</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Common Stock, par value $.01 per share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>MD</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>New York Stock Exchange</B></TD></TR>
</TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth
company&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%" VALIGN="top" ALIGN="left"><B>Item&nbsp;7.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Regulation FD Disclosure. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MEDNAX, Inc., a Florida corporation (the &#147;Company&#148;), will host an investor conference call and webcast on Friday, June&nbsp;5, 2020,
at 9:00 a.m. ET, to provide a business update. The conference call and webcast may be accessed in the &#147;Investors&#148; section of the Company&#146;s website, www.mednax.com. A slide presentation to accompany the conference call and webcast,
which may be used in whole or in part, and subject to modification, will be posted to the &#147;Investors&#148; section of the Company&#146;s website at approximately 8:45 a.m. ET on June&nbsp;5, 2020. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Other Events. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;5, 2020, the Company issued a press release announcing a number of further steps it is taking as part of its aggressive
transformational activity to position the Company for long-term, sustainable growth. One such step identified by the Company in the press release is the intent to change the Company&#146;s name to its original name, Pediatrix Medical Group, Inc.,
subject to and following approval of the name change by the Company&#146;s shareholders at the Company&#146;s 2020 Annual Meeting of Shareholders on August&nbsp;11, 2020. A copy of the Company&#146;s press release is attached as Exhibit&nbsp;99.1 to
this Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and is incorporated herein by reference. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain statements and information in this Current Report on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K&nbsp;may</FONT> be deemed to
contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements
may include, but are not limited to, statements relating to the Company&#146;s objectives, plans and strategies, and all statements, other than statements of historical facts, that address activities, events or developments that we intend, expect,
project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as &#147;believe,&#148; &#147;hope,&#148; &#147;may,&#148; &#147;anticipate,&#148; &#147;should,&#148; &#147;intend,&#148;
&#147;plan,&#148; &#147;will,&#148; &#147;expect,&#148; &#147;estimate,&#148; &#147;project,&#148; &#147;positioned,&#148; &#147;strategy&#148; and similar expressions, and are based on assumptions and assessments made by the Company&#146;s
management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this Current Report on <FONT
STYLE="white-space:nowrap">Form&nbsp;8-K&nbsp;are</FONT> made as of the date hereof, and the Company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking
statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are
described in the Company&#146;s most recent Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K&nbsp;and</FONT> its Quarterly Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q,&nbsp;including</FONT> the sections entitled
&#147;Risk Factors&#148;, as well the Company&#146;s current reports on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K,&nbsp;filed</FONT> with the Securities and Exchange Commission, and include the impact of the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak on the Company and its financial condition and results of operations; the effects of economic conditions on the Company&#146;s business; the effects of the Affordable Care Act and potential
changes thereto or a repeal thereof; the Company&#146;s relationships with government-sponsored or funded healthcare programs, including Medicare and Medicaid, and with managed care organizations and commercial health insurance payors; the
Company&#146;s ability to comply with the terms of its debt financing arrangements; the impact of the divestiture of the Company&#146;s anesthesiology medical group; whether the Company will be able to complete the divestiture of its radiology
medical group and the terms of any such divestiture; the timing and contribution of future acquisitions; the effects of share repurchases; and the effects of the Company&#146;s transformation initiatives, including its reorientation on, and growth
strategy for, its pediatrics and obstetrics business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Important Additional Information and Where You Can Find It </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company, its directors and certain of its executive officers may be deemed to be participants in a solicitation of proxies from the
Company&#146;s shareholders at its 2020 Annual Meeting of Shareholders in connection with the matters to be considered at the 2020 Annual Meeting of Shareholders. Information regarding the Company&#146;s directors and executive officers and their
respective interests in the Company, by </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
security holdings or otherwise, will be set forth in the Company&#146;s Definitive Proxy Statement for its 2020 Annual Meeting of Shareholders, to be filed with the Securities and Exchange
Commission (the &#147;SEC&#148;), and reports filed by the Company and ownership forms filed by its directors and executive officers with the SEC. The Company will furnish its Definitive Proxy Statement for its 2020 Annual Meeting of Shareholders to
shareholders entitled to vote at the meeting and will file a copy with the SEC. The Company urges its shareholders to carefully read the Definitive Proxy Statement for its 2020 Annual Meeting of Shareholders, and any other relevant documents filed
by the Company with the SEC, when available because they will contain important information. Shareholders will be able to receive the proxy statement and other relevant documents free of charge at the SEC&#146;s website at www.sec.gov or at
www.mednax.com. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Statements and Exhibits. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)<I>&nbsp;Exhibits</I> </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Exhibit Index </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit</B><br><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description of Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release of MEDNAX, Inc. dated June&nbsp;5, 2020.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>104</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Cover Page Interactive Data File (embedded within the Inline XBRL document).</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>MEDNAX, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: June&nbsp;5, 2020</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Stephen D. Farber</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stephen D. Farber</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chief Financial
Officer</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g921216g0605050400013.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FOR MORE INFORMATION: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Charles Lynch </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vice President, Strategy and Investor Relations
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">954-384-0175</FONT></FONT> ext. 5692 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>charles_lynch@mednax.com </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>FOR IMMEDIATE RELEASE
</U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEDNAX Announces Significant Progress in Strategic Transformation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Company Intends to Return to Original Name, Pediatrix Medical Group; to Refocus as </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Dedicated Pediatrics&nbsp;&amp; Obstetrics Organization </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Announces Intent to Sell MEDNAX Radiology Solutions </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Repays Revolving Line of Credit and Provides Business Update </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FORT LAUDERDALE, Fla.&#151;June 5, 2020&#151;</B>MEDNAX, Inc. (NYSE: MD), a leading health solutions partner specializing in prenatal, neonatal, pediatric,
and radiology services, today announced a number of further steps it is taking as part of its aggressive transformational activity to position the Company for long-term, sustainable growth. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As previously announced, since 2018 MEDNAX has been conducting a comprehensive review of its businesses. In that time, the MEDNAX Board of Directors and
management team have taken decisive strategic and financial actions to position the Company for the future, including implementing significant operational improvements and efficiencies; leveraging the insights of leading consultants; selling
MedData; selling its American Anesthesiology medical group; and enhancing its organizational and leadership structure to align with a refocused business model. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The MEDNAX Board of Directors and management believe that continuing to implement the Company&#146;s strategic priorities and reorienting the Company as a
dedicated, streamlined pediatrics and obstetrics business will provide the greatest near- and long-term benefits for all of its stakeholders. Accordingly, MEDNAX intends to return to its original company name, Pediatrix Medical Group, Inc., pending
approval by the Company&#146;s shareholders at its 2020 annual meeting in August. The Company will continue trading under its current ticker symbol (NYSE: MD). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;The initiatives we are outlining today signify our return to our roots as a leading provider of
women&#146;s and children&#146;s care, and are a culmination of our efforts to concentrate on our core practice areas and refine our strategy for growth and profitability,&#148; said Roger J. Medel, M.D., Chief Executive Officer of MEDNAX. &#147;As
Pediatrix Medical Group, we will become an organization wholly dedicated to women&#146;s and children&#146;s services, and one that will continue to drive innovations to improve the quality and experience of patient care for years to come.&#148;
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Return to </B><B><I>Pediatrix Medical Group</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Today, clinicians affiliated with the Company&#146;s Pediatrix and Obstetrix medical groups care for more than 1&nbsp;million babies a year. These medical
groups represent the leading provider of specialty women&#146;s health services and pediatric care in the U.S., with a network of more than 2,200 physicians providing services across 17 subspecialty lines. Pediatrix- and Obstetrix-affiliated
clinicians care for nearly 25% of the country&#146;s NICU babies and make 1,900 maternal fetal medicine visits per day in over 400 facilities across 40 states and Puerto Rico. In 2019, the Company&#146;s Pediatrix and Obstetrix medical groups
generated approximately $1.8&nbsp;billion in revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MEDNAX has been implementing a number of key strategic priorities to support its path forward and
has developed a plan to position Pediatrix Medical Group to drive sustained growth, which is based on: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Benefitting from proven leadership and a focused organizational model. </B>With unmatched experience over the
past 40+ years, and the ongoing benefits of its refocused organizational structure, the Company believes that the Pediatrix management team is well positioned to <FONT STYLE="white-space:nowrap">re-energize</FONT> the field and accelerate growth.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Retaining national and local reach.</B> With its extensive national footprint, the Pediatrix organization will
focus on leveraging its strong market position to build its organic growth pipeline. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Capitalizing on growth opportunities.</B> Women&#146;s and children&#146;s health services represent a large
addressable market and the Company believes Pediatrix is positioned to drive incremental growth through robust sales initiatives and targeted <FONT STYLE="white-space:nowrap">tuck-in</FONT> and strategic acquisitions. Additionally, the Company
believes it can generate additional growth via expansion into adjacent clinical services, as well as innovation in care delivery models supported by digital health, data and analytics, and genomics. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Our Pediatrix&nbsp;&amp; Obstetrix medical groups have strengthened and evolved over the past few decades, and we have been steadfast in our unwavering
commitment to providing patients with </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the highest level of care,&#148; said Mack Hinson, M.D., President of MEDNAX&#146;s Pediatrix&nbsp;&amp; Obstetrix medical groups. &#147;We have cultivated the most talented group of pediatric
and obstetric healthcare providers in the country, and I am proud to see the Company turn its full focus towards the continued development of these important practice areas. We look forward to building on our strong foundation in women&#146;s and
children&#146;s health care, and we will continue to invest our resources and strategies to deliver the best patient care and experience possible.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intent to Sell MEDNAX Radiology Solutions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MEDNAX today
confirmed that it has been reviewing strategic alternatives for its radiology medical group, MEDNAX Radiology Solutions. Prior to the onset of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, MEDNAX had been in advanced discussions to
divest this organization and plans to move forward with a divestiture, when market conditions are appropriate. MEDNAX intends to apply the proceeds from a sale of MEDNAX Radiology Solutions towards debt reduction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of the Company&#146;s 2020 financial expectations that MEDNAX provided prior to the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic, MEDNAX Radiology Solutions was expected to contribute approximately $550&nbsp;million and $90&nbsp;million in revenue and Adjusted EBITDA, respectively, to the Company&#146;s operating results for the year. In accordance with GAAP
accounting, operating results for MEDNAX Radiology Solutions will continue to be reported as part of MEDNAX&#146;s continuing operations at this time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MEDNAX does not intend to provide further public comments on this strategic alternatives process. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MEDNAX Business Update </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As previously disclosed, during
the 2020 second quarter to date, MEDNAX&#146;s operations have been significantly impacted by reductions in patient volumes and revenue as a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. However, the Company&#146;s
operations began to normalize in an accelerating fashion during the month of May. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the Company&#146;s radiology services medical group, during the
month of April, study volumes declined by approximately 50&nbsp;percent versus the prior year. On a preliminary basis, the Company estimates that study volumes declined by approximately 30 to 35&nbsp;percent during the month of May, with those
declines lessening to approximately 25&nbsp;percent by the end of the month. In the Company&#146;s office-based women&#146;s and children&#146;s medical groups, during the month of April, patient volumes declined by approximately 25&nbsp;percent
versus the prior year. On a preliminary basis, the Company estimates that during the month of May, patient volumes declined by approximately 10 to 15&nbsp;percent versus the prior year, with those declines lessening to approximately 10&nbsp;percent
by the end of the month. Finally, the Company estimates that aggregate patient volumes in its hospital-based pediatric medical groups, including neonatology and neonatology-related services, pediatric intensive care, and other pediatric services,
experienced only minor, single-digit percentage declines through the months of April and May. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In total, the Company estimates that the reduction to consolidated revenue as a result of these declines in
patient volume during the month of May, as compared to the prior year, was in the range of approximately 10 to 15&nbsp;percent. During the month of April, the Company estimates that this impact was approximately 25&nbsp;percent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As previously announced, MEDNAX implemented a number of actions to preserve its financial flexibility and partially mitigate the significant impact of <FONT
STYLE="white-space:nowrap">COVID-19</FONT> on the Company. MEDNAX and its affiliated practices have also received, and expect to receive, certain funds available to healthcare providers under the Coronavirus Aid, Relief, and Economic Security Act
(the &#147;CARES Act&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, in recent weeks, following the divestiture of American Anesthesiology on May&nbsp;6, 2020, MEDNAX has taken
action to remove approximately $10&nbsp;million in annualized expenses, and the Company believes there are significant additional opportunities to reshape the cost structure of its support services to affiliated practices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Finally, during the month of May, MEDNAX repaid all borrowings on its revolving credit facility. As of May&nbsp;31, the Company&#146;s debt consisted solely
of $1.75&nbsp;billion in senior notes, and MEDNAX had total cash on hand of $90&nbsp;million, resulting in net debt of $1.66&nbsp;billion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Our
highest priority during this challenging period has been to ensure that MEDNAX is able to support its clinicians in their mission to take great care of their patients,&#148; said Stephen D. Farber, Executive Vice President and Chief Financial
Officer. &#147;Our ability to maintain financial flexibility is key to meeting this priority. The steps we have taken, and will continue to take, demonstrate our commitment to retain a strong balance sheet with moderate leverage and meaningful
liquidity. Moreover, we believe these steps will help ensure that MEDNAX continues to meet its commitments to its patients, its affiliated physicians, and its hospital partners long into the future.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conference Call Today </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MEDNAX, Inc., will host an
investor conference call to discuss today&#146;s announcements at 9:00 a.m., ET today. The conference call Webcast may be accessed from the Company&#146;s Website, www.mednax.com. A telephone replay of the conference call will be available from 1:30
p.m. ET today through midnight ET June&nbsp;19, 2020 by dialing 866.207.1041, access Code 2325797. The replay will also be available at <U>www.mednax.com</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A slide presentation accompanying today&#146;s conference call will also be available on the Company&#146;s website at approximately 8:45 a.m., ET today. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Important Additional Information and Where You Can Find It </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MEDNAX, Inc. (the &#147;Company&#148;), its directors and certain of its executive officers may be deemed to be participants in a solicitation of proxies from
the Company&#146;s shareholders at its 2020 Annual Meeting of Shareholders in connection with the matters to be considered at the 2020 Annual Meeting of Shareholders. Information regarding the Company&#146;s directors and executive officers and
their respective interests in the Company, by security holdings or otherwise, will be set forth in the Company&#146;s Definitive Proxy Statement for its 2020 Annual Meeting of Shareholders, to be filed with the Securities and Exchange Commission
(the &#147;SEC&#148;), and reports filed by the Company and ownership forms filed by its directors and executive officers with the SEC. The Company will furnish its Definitive Proxy Statement for its 2020 Annual Meeting of Shareholders to
shareholders entitled to vote at the meeting and will file a copy with the SEC. The Company urges its shareholders to carefully read the Definitive Proxy Statement for its 2020 Annual Meeting of Shareholders, and any other relevant documents filed
by the Company with the SEC, when available because they will contain important information. Shareholders will be able to receive the proxy statement and other relevant documents free of charge at the SEC&#146;s website at www.sec.gov or at
<U>www.mednax.com</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ABOUT MEDNAX </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MEDNAX, Inc. is
a national health solutions partner comprised of the nation&#146;s leading providers of physician services. Physicians and advanced practitioners practicing as part of MEDNAX are reshaping the delivery of care within their specialties and
subspecialties, using evidence-based tools, continuous quality initiatives, consulting services, clinical research and telemedicine to enhance patient outcomes and provide high-quality, cost-effective care. The Company was founded in 1979, and
today, through its affiliated professional corporations, MEDNAX provides services through a network of more than 3,000 physicians in all 50 states and Puerto Rico. Additional information is available at <U>www.mednax.com</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Certain statements and information in this press release may be deemed to contain forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995, Section&nbsp;27A of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may include, but are not
limited to, statements relating to the Company&#146;s objectives, plans and strategies, and all statements, other than statements of historical facts, that address activities, events or developments that we intend, expect, project, believe or
anticipate will or may occur in the future. These statements are often characterized by terminology such as &#147;believe,&#148; &#147;hope,&#148; &#147;may,&#148; &#147;anticipate,&#148; &#147;should,&#148; &#147;intend,&#148; &#147;plan,&#148;
&#147;will,&#148; &#147;expect,&#148; &#147;estimate,&#148; &#147;project,&#148; &#147;positioned,&#148; &#147;strategy&#148; and similar expressions, and are based on assumptions and assessments made by the Company&#146;s management in light of
their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are
</I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>
made as of the date hereof, and the Company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking
statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are
described in the Company&#146;s most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and its Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> including the sections entitled &#147;Risk Factors&#148;,
as well the Company&#146;s current reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> filed with the Securities and Exchange Commission, and include the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak on the Company
and its financial condition and results of operations; the effects of economic conditions on the Company&#146;s business; the effects of the Affordable Care Act and potential changes thereto or a repeal thereof; the Company&#146;s relationships with
government-sponsored or funded healthcare programs, including Medicare and Medicaid, and with managed care organizations and commercial health insurance payors; the Company&#146;s ability to comply with the terms of its debt financing arrangements;
the impact of the divestiture of the Company&#146;s anesthesiology medical group; whether the Company will be able to complete the divestiture of its radiology medical group and the terms of any such divestiture; the timing and contribution of
future acquisitions; the effects of share repurchases; and the effects of the Company&#146;s transformation initiatives, including its reorientation on, and growth strategy for, its pediatrics and obstetrics business. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g921216g0605050400013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g921216g0605050400013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !4 2D# 2(  A$! Q$!_\0
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MG KMY4<?,RQ_:^I_]!*]_P# A_\ &C^U]3_Z"5[_ .!#_P"-=?\ \*>\9_\
M/C;_ /@0*/\ A3WC/_GQM_\ P(%9^TI=T:>SJ]F<A_:^I_\ 02O?_ A_\:/[
M7U/_ *"5[_X$/_C77_\ "GO&?_/C;_\ @0*XW4;"XTO4KFPNU"W%O(8Y%!R
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M K.U#0=)U:99M0TZWN9$7:K2H&('7%80K-3YY:FTZ2<.2.A\=9'K7T=\$/\
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M,ZM@8XXZ\U;\0:T-#TX7"V[7$KN$CA0X+GDG\@"?PKFO!%QIRP:?;"74!?B
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M8RTCMT K-\9H[Z5:!$9B+^W)"C/&\4OBR"<P:??PPR3_ &"\2XDBC&69!D'
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LBB@!<T9HHH 2C-%% !1110 N:3-%% !FBBB@ S1110 N:2BB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
